Sofwave Medical reported Q2 and first-half 2026 financial results and business highlights, with revenue acceleration driven by adoption of its ultrasonic RF microneedling platform. The company continues to gain traction in the competitive RF space.
Devices & Tech
Sofwave Q2 Revenue Accelerates on Ultrasonic Demand
Ultrasonic RF microneedling platform shows strong uptake; company reports Q2 and H1 results.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Ultrasonic RF microneedling platform driving revenue acceleration in competitive device market.
Sofwave's ultrasonic RF approach differentiates on depth control and thermal profile compared to conventional RF microneedling, which can appeal to practices seeking a clinical edge. The platform's economics—capex, per-treatment consumable cost, and patient pricing tolerance—will determine whether it gains meaningful share against entrenched players like InMode and Cutera. Monitor Sofwave's installed base growth and average revenue per device as indicators of market acceptance.
Source: original report ↗
Frequently asked questions
What is ultrasonic RF microneedling and how does it differ from regular RF microneedling?
Ultrasonic RF microneedling combines radiofrequency energy with ultrasonic technology and microneedles to deliver controlled thermal energy at precise depths in the skin. Sofwave's ultrasonic RF approach differentiates on depth control and thermal profile compared to conventional RF microneedling, allowing practitioners to target specific skin layers with greater precision and potentially achieve better clinical outcomes.
Is Sofwave competing with InMode and Cutera in the RF microneedling market?
Yes, Sofwave competes in the RF microneedling space against entrenched players like InMode and Cutera. The company's market success will depend on its platform's economics—including capital expenditure, per-treatment consumable costs, and patient pricing tolerance—as well as its ability to demonstrate clinical advantages and build an installed base.
What metrics should medspa owners track to evaluate Sofwave's market traction?
Monitor Sofwave's installed base growth and average revenue per device as key indicators of market acceptance and competitive positioning. These metrics will reveal whether practices are adopting the technology and whether the platform's unit economics support profitability for both the company and clinic operators.
What are the key economic factors that determine if Sofwave gains market share?
The platform's capital expenditure requirements, per-treatment consumable costs, and patient pricing tolerance are critical to market adoption. Practices will evaluate whether Sofwave's upfront investment, ongoing supply costs, and reimbursement potential compare favorably to competing RF microneedling systems.
Why is Sofwave seeing revenue acceleration in Q2 2026?
Sofwave reported Q2 and first-half 2026 revenue acceleration driven by strong adoption of its ultrasonic RF microneedling platform. The company continues to gain traction in the competitive RF space as practices recognize the clinical differentiation offered by its depth control and thermal profile advantages.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.